(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 October 2001 (11.10.2001)

PCT

(10) International Publication Number
WO 01/74368 A1

(51) International Patent Classification[7]: A61K 31/661, 31/282, 31/337, 41/00, A61P 35/00 // (A61K 31/661, 31:282) (A61K 31/661, 31:337)

(21) International Application Number: PCT/GB01/01317

(22) International Filing Date: 27 March 2001 (27.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0007740.4	31 March 2000 (31.03.2000)	GB
0013927.9	8 June 2000 (08.06.2000)	GB
0014908.8	20 June 2000 (20.06.2000)	GB

(71) Applicant *(for all designated States except US)*: **ANGIOGENE PHARMACEUTICALS LTD.** [GB/GB]; 14 Plowden Park, Aston Rowant, Watlington, Oxfordshire OX9 5SX (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DAVIS, Peter, David** [GB/GB]; 14 Plowden park, Aston Rowant, Watlington, Oxfordshire OX9 5SX (GB). **DOUGHERTY, Graeme** [GB/US]; Apartment 506, 919 Levering Avenue, Los Angeles, CA 90024 (US).

(74) Agent: **BRYANT, Tracey**; AstraZeneca, Global Intellectual Property, P.O. Box 272, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4GR (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:


— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/74368 A1

(54) Title: COMBINATION THERAPIES WITH VASCULAR DAMAGING ACTIVITY



(57) Abstract: The invention relates to a method for the production of a vascular damaging effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6126 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of one of the following therapies: i) ionising radiation; ii) a platinum anti-tumour agent; and iii) a taxane. The invention also relates to the use of ZD6126 and one of the above therapies in the manufacture of a medicament for use in the production of a vascular damaging effect in a warm-blooded animal such as a human and to pharmaceutical compositions and kits each comprising ZD6126 and one of a platinum anti-tumour agent and a taxane.